September 24, 2021 - Frequency Therapeutics, Inc announced that 4 additional SNHL subjects from its FX-322-111 study achieved “statistically significant hearing improvements.”

July 17, 2019 - Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

February 13, 2023 - (RTTNews) - Frequency Therapeutics, Inc. (FREQ) reported clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss. The study failed to achieve its primary efficacy endpoint of an improvement in speech perception

September 13, 2020 - These new data build upon Phase ... with chronic moderate to moderately severe SNHL. These patients had received a single intratympanic dose of FX-322 in a double-blind, placebo-controlled study, and had been evaluated for 90 days....

This is a Phase 1b placebo-controlled, double-blind, randomized, single-dose safety study of intratympanic FX-322 dosed in subjects with age-related sensorineural hearing loss.~Approximately 30 subjects are planned to be enrolled in this study.

December 12, 2022 - FX-322 continues to have a favorable safety profile and we are aligned with FDA on the primary speech perception endpoint. With a successful outcome of this single-dose study, our intent is to advance the program into Phase 3 trials,” said David L.

March 23, 2021 - Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results sho

August 3, 2024 - The case revolves around Frequency Therapeutics, a biotech startup that was developing a treatment for severe sensorineural hearing loss called "FX-322". Initial trials were positive, but subsequent testing yielded disappointing results, causing a sharp drop in Frequency's stock price.

FX-322: a Stem cells stimulants Drug, Initially developed by Frequency Therapeutics, Inc., Now, its global highest R&D status is Phase 2, Mechanism: Stem cells stimulants, Therapeutic Areas: Nervous System Diseases,Otorhinolaryngologic Diseases, Active Org.: Frequency Therapeutics, Inc..

August 7, 2024 - Frequency Therapeutics Inc. has announced the cessation of its FX-322 and FX-345 programs designed to help people with sudden or noise-induced sensorineural hearing loss (SNHL) only a few months after biotech hearing loss developer Otonomy closed its doors. What does this mean for people with ...

October 24, 2019 - In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss.

March 23, 2021 - In contrast to its published results in February, Frequency Therapeutics latest trial showed four weekly injections of its FX-322 in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing.

April 10, 2019 - Frequency Therapeutics has reported positive data from a Phase I/II clinical trial of investigational drug FX-322 intended for hearing restoration.

February 8, 2023 - In the phase 2a study, Frequency tested the drug, FX-322, in nearly 100 patients with mild to moderate sensorineural hearing loss who had suddenly lost their hearing or have a history of chronic noise exposure. The patients received four weekly injections through their eardrum.

March 18, 2021 - Frequency Therapeutics (Woburn, Mass.) recently announced promising data related to its experimental FX-322 drug.

February 23, 2021 - Individuals with stable SNHL that received a single dose of FX-322 showed improvements in the number of words recognized in quiet from baseline to day 90 in the WR test (p=0.029) and the level of background noise in which words could be identified in the WIN test (p=0.012).

September 19, 2019 - No patient had worsening of hearing loss during the trial, said King. However, the results showed no pure tone improvement in the between-group comparison. Individual patient data showed that four patients in the FX-322 group had a 10-decibel improvement at 8,000 Hz at 90 days, whereas no patient ...